Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Inventory (2018 - 2025)

Historic Change in Inventory for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$208175.0.

  • BioNexus Gene Lab's Change in Inventory fell 15846.41% to -$208175.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$25103.0, marking a year-over-year increase of 3658.14%. This contributed to the annual value of -$160387.0 for FY2023, which is 12947.71% down from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Change in Inventory is -$208175.0, which was down 15846.41% from -$382481.0 recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Change in Inventory peaked at $970080.0 during Q4 2022, and registered a low of -$819988.0 during Q2 2021.
  • Over the past 5 years, BioNexus Gene Lab's median Change in Inventory value was -$45850.0 (recorded in 2021), while the average stood at -$5105.2.
  • Within the past 5 years, the most significant YoY rise in BioNexus Gene Lab's Change in Inventory was 2319268.68% (2021), while the steepest drop was 267736.08% (2021).
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Change in Inventory stood at -$34236.0 in 2021, then skyrocketed by 2933.51% to $970080.0 in 2022, then crashed by 129.99% to -$290889.0 in 2023, then surged by 222.41% to $356073.0 in 2024, then crashed by 158.46% to -$208175.0 in 2025.
  • Its Change in Inventory stands at -$208175.0 for Q3 2025, versus -$382481.0 for Q2 2025 and $209480.0 for Q1 2025.